Pharmaceutical Grade Weight Loss Peptide Liraglutide

China Pharmaceutical Grade Weight Loss Peptide Liraglutide, Find details about China Liraglutide Powder, Liraglutide from Pharmaceutical Grade Weight Loss Peptide Liraglutide

Model NO.
WH0956
Product Name
Liraglutide Peptide Powder
Usage
Weight Loss Peptide
CAS
204656-20-2
Appearance
White Powder
Mf
C172h265n43o51
Sample
Available
Payment
L/C, T/T, D/P, D/a
MOQ
Any Quantity
Grade
Pharmaceutical Grade;Cosmetic Grade
Storage
Cool Dry Place
MW
486.42
Brand
Wh
Transport Package
Bag or Drum
Specification
1kg/bag 25kg/drum
Origin
China
Model NO.
WH0956
Product Name
Liraglutide Peptide Powder
Usage
Weight Loss Peptide
CAS
204656-20-2
Appearance
White Powder
Mf
C172h265n43o51
Sample
Available
Payment
L/C, T/T, D/P, D/a
MOQ
Any Quantity
Grade
Pharmaceutical Grade;Cosmetic Grade
Storage
Cool Dry Place
MW
486.42
Brand
Wh
Transport Package
Bag or Drum
Specification
1kg/bag 25kg/drum
Origin
China

Product Description

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli n secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.
 

Product Name:Liraglutide
CAS:204656-20-2
Other namesLiraglutide
MF:C172H265N43O51
EINECS:N/A
Product Categories:Vitamins
Appearancewhite powder
Brand Name:YYC 
FormPowder
Place of Origin:Shaanxi, China (Mainland)
Packaging:Bottle, Can, Drum, Plastic Contain
Standard:USP EP JP etc.
Purity:99.0%
Introduction: Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates in  sulin secretion. 
 
Pharmaceutical Grade Weight Loss Peptide Liraglutide
Pharmaceutical Grade Weight Loss Peptide Liraglutide
 

Function

Medical uses
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

 

Appliction

 

Medical uses
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.



Pharmaceutical Grade Weight Loss Peptide Liraglutide

Specification

 

Pharmaceutical Grade Weight Loss Peptide Liraglutide

 

Company Information

Pharmaceutical Grade Weight Loss Peptide Liraglutide

Packaging & Shipping

 

Pharmaceutical Grade Weight Loss Peptide Liraglutide

OUR CERTIFICATE

Pharmaceutical Grade Weight Loss Peptide Liraglutide

Pharmaceutical Grade Weight Loss Peptide Liraglutide

Factory Show

Pharmaceutical Grade Weight Loss Peptide LiraglutidePharmaceutical Grade Weight Loss Peptide Liraglutide

Pharmaceutical Grade Weight Loss Peptide Liraglutide